Copelan E A, Tutschka P J
Bone Marrow Transplant Program, Ohio State University, Columbus 43210.
Bone Marrow Transplant. 1988 Jul;3(4):363-5.
We report the use of busulfan and cyclophosphamide as conditioning before allogeneic bone marrow transplantation for a 38-year-old man with multiple myeloma. Three months post-transplant the monoclonal IgA band previously present was no longer detectable in the serum and plasma cells were no longer visible in the marrow. The patient died on day 93 with fungal infection. We conclude that the combination of busulfan and cyclophosphamide could be valuable before transplant for other patients with multiple myeloma.
我们报告了一名38岁的多发性骨髓瘤男性患者在异基因骨髓移植前使用白消安和环磷酰胺进行预处理的情况。移植后三个月，先前存在的单克隆IgA条带在血清中不再可检测到，骨髓中也不再可见浆细胞。患者在第93天死于真菌感染。我们得出结论，对于其他多发性骨髓瘤患者，白消安和环磷酰胺联合使用在移植前可能具有价值。
